Intravenous iron sucrose in peritoneal dialysis patients with renal anemia

Peritoneal Dialysis International

Volumn 28, Issue 2, 2008, Pages 149-154

  Li, Han ^a   Wang, Shi Xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Erythropoietin (EPO); Iron; Iron sucrose; Renal anemia

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERROUS SUCCINATE; FOLIC ACID; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CHINA; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL ANEMIA; SEX RATIO; SHOCK; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

EID: 42349091970     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802800210     Document Type: Article

References (20)

1. Portoles J, Lopez-Gomez JM, Aljama P. Anemia management and treatment response in patients on hemodialysis: the MAR study. J Nephrol 2006; 19:352-60.
2. Riedel MK, Morgenstern T. [Iron replacement in hemodialysis patients with a normal serum ferritin Level. In German] Dtsch Med Wochenschr 2004; 129:1849-53.
3. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13:381-4.
4. Charytan C, Levin N, Saloum MA. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37:300-7.
5. Michael B, Coyne DW, Steven C. Sodium ferric gluconate complexin hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-9.
6. Zhang Z. The Criteria of the Diagnosis and Treatment of Hematological Diseases. 2nd ed. Beijing: The Science Press; 1998: 10-13.
7. Teehan BP, Sigler MH, Brown JM, Benz RL, Gilgore GS, Schleifer CR, et al. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplant Proc 1996; 212:63.
8. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006; 38:295-310.
9. Petersen H, Jensen KE, Haghfelt TH. [The cardio-renal anemia syndrome: what is it? With a focus on congestive heartfailure. In Danish] Ugeskr Laeger 2006; 168:1864-7.
10. Roman RM, Lobo PI, Taylor RP, Goodkin DA, LaBrecque J, Powers KL, et al. Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythro-poietin. J Am Soc Nephrol 2004; 15:1339-46.
11. Spiegel DM. Anemia management in chronic kidney disease: what have we Learned after 17 years? Semin Dial 2006; 19:269-72.
12. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the Last 5 years. Nephrol Dial Transplant 2005; 20(Suppl 3):iii3-24.
13. Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transplant 2001; 16:1879-84.
14. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 1998; 9:664-8.
15. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. [Erratum published in Am J Kidney Dis 2006; 48:518.] Am J Kidney Dis 2006; 47(5 Suppl 3):S11-145.
16. Jayakumar S. Iron-dextran anaphylactic-Like reaction after a negative test dose and subsequent successful administration of three doses. Dial Transplant 2000; 29: 198-201.
17. Hood SA, O'Brien M, Higgins R. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease. Nephrol Nurs J 2000; 27: 41-2.
18. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products. Am J Nephrol 2000; 20:455-62.
19. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378-82.
20. Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V, Bicik Z, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 2005; 46:255-64.